| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
35,380,000 |
| Market
Cap: |
35.38(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1 - $1.25 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Evofem Biosciences is a commercial-stage biopharmaceutical company committed to developing and commercializing products to address unmet needs in women's sexual and reproductive health, including woman-controlled contraception and protection from certain sexually transmitted infections. Co.'s commercial product, Phexxi, is the U.S. Food and Drug Administration (FDA)-approved, hormone-free, woman-controlled, prescription contraceptive gel for women. Co. is evaluating Phexxi for two potential new indications: the prevention of chlamydia and the prevention of gonorrhea in women. The FDA has designated Phexxi, using the investigational name EVO100, as a Qualified Infectious Disease Product.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
114 |
114 |
114 |
| Total Sell Value |
$0 |
$10 |
$10 |
$10 |
| Total People Sold |
0 |
2 |
2 |
2 |
| Total Sell Transactions |
0 |
2 |
2 |
2 |
| End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  File Justin J. |
Chief Financial Officer |
• – – |
2019-08-22 |
4 |
D |
$5.13 |
$7,993 |
D/D |
(1,558) |
217,455 |
|
- |
|
| Barrans Russell |
Chief Commercial Officer |
• – – |
2019-08-22 |
4 |
D |
$5.13 |
$4,935 |
D/D |
(962) |
216,197 |
|
- |
|
| Culwell Kelly |
Chief Medical Officer |
• – – |
2019-08-22 |
4 |
D |
$5.13 |
$4,432 |
D/D |
(864) |
54,912 |
|
- |
|
| Fitzpatrick Alexander A |
General Counsel and Secretary |
• – – |
2019-08-22 |
4 |
D |
$5.13 |
$6,648 |
D/D |
(1,296) |
97,252 |
|
- |
|
| Pelletier Saundra L |
Chief Executive Officer |
• • – |
2019-08-22 |
4 |
D |
$5.13 |
$25,255 |
D/D |
(4,923) |
447,333 |
|
- |
|
| Barrans Russell |
Chief Commercial Officer |
• – – |
2019-07-08 |
4 |
D |
$4.99 |
$66,152 |
D/D |
(13,257) |
217,159 |
|
- |
|
| Barrans Russell |
Chief Commercial Officer |
• – – |
2019-07-08 |
4 |
A |
$0.00 |
$0 |
D/D |
150,000 |
230,416 |
|
- |
|
| Lynch Thomas G |
Director |
– • – |
2019-06-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
37,500 |
212,500 |
|
- |
|
| Fitzpatrick Alexander A |
General Counsel and Secretary |
• – – |
2019-06-10 |
4 |
D |
$6.36 |
$49,462 |
D/D |
(7,777) |
98,548 |
|
- |
|
| Barrans Russell |
Chief Commercial Officer |
• – – |
2019-06-10 |
4 |
D |
$6.36 |
$37,937 |
D/D |
(5,965) |
80,416 |
|
- |
|
| Culwell Kelly |
Chief Medical Officer |
• – – |
2019-06-10 |
4 |
D |
$6.36 |
$32,989 |
D/D |
(5,187) |
55,776 |
|
- |
|
| File Justin J. |
Chief Financial Officer |
• – – |
2019-06-10 |
4 |
D |
$6.36 |
$64,777 |
D/D |
(10,185) |
219,013 |
|
- |
|
| Pelletier Saundra L |
Chief Executive Officer |
• • – |
2019-06-10 |
4 |
D |
$6.36 |
$227,853 |
D/D |
(35,826) |
452,256 |
|
- |
|
| Invesco Ltd. |
10% Owner |
– – • |
2019-06-10 |
4 |
B |
$4.50 |
$9,999,999 |
I/I |
2,222,222 |
11,812,910 |
1.5 |
- |
|
| Pdl Biopharma, Inc. |
10% Owner |
– – • |
2019-06-10 |
4 |
B |
$4.50 |
$30,000,002 |
D/D |
6,666,667 |
13,333,334 |
2.45 |
- |
|
| Kamdar Kim P. |
Director |
– • – |
2019-05-22 |
4 |
A |
$0.00 |
$0 |
D/D |
4,287 |
4,287 |
|
- |
|
| Kamdar Kim P. |
Director |
– • – |
2019-05-21 |
4 |
S |
$5.07 |
$3,321 |
I/I |
(655) |
0 |
|
- |
|
| Pdl Biopharma, Inc. |
10% Owner |
– – • |
2019-04-11 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
6,666,667 |
|
- |
|
| File Justin J. |
Chief Financial Officer |
• – – |
2019-04-01 |
4 |
D |
$3.55 |
$4,587 |
D/D |
(1,292) |
229,198 |
|
- |
|
| Culwell Kelly |
Chief Medical Officer |
• – – |
2019-04-01 |
4 |
D |
$3.55 |
$3,628 |
D/D |
(1,022) |
60,963 |
|
- |
|
| Barrans Russell |
Chief Commercial Officer |
• – – |
2019-04-01 |
4 |
D |
$3.55 |
$4,118 |
D/D |
(1,160) |
86,381 |
|
- |
|
| Pelletier Saundra L |
Chief Executive Officer |
• • – |
2019-04-01 |
4 |
D |
$3.55 |
$13,245 |
D/D |
(3,731) |
488,082 |
|
- |
|
| Fitzpatrick Alexander A |
General Counsel and Secretary |
• – – |
2019-04-01 |
4 |
D |
$3.55 |
$4,608 |
D/D |
(1,298) |
106,325 |
|
- |
|
| File Justin J. |
Chief Financial Officer |
• – – |
2019-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
230,490 |
|
- |
|
| Fitzpatrick Alexander A |
General Counsel and Secretary |
• – – |
2019-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
107,623 |
|
- |
|
194 Records found
|
|
Page 5 of 8 |
|
|
